Overview
Bivalirudin is a synthetic 20-amino acid peptide that functions as a direct thrombin inhibitor. It was developed as an alternative to heparin, particularly for patients with heparin-induced thrombocytopenia (HIT) or those undergoing percutaneous coronary interventions (PCI). The drug binds reversibly to both free and clot-bound thrombin, offering predictable anticoagulation effects with a short half-life of approximately 25 minutes. As a bivalent inhibitor, Bivalirudin interacts with both the active site and exosite 1 of thrombin, providing more complete thrombin inhibition compared to univalent inhibitors. Its synthetic nature eliminates batch-to-batch variability concerns associated with heparin, making it particularly valuable in critical care settings where precise anticoagulation control is required.
Physical and Chemical Properties
Bivalirudin appears as a white to off-white lyophilized powder that is soluble in water. The compound has a molecular weight of 2180.3 g/mol and is stable when stored properly at 2-8°C. The peptide sequence consists of D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu, designed to mimic the C-terminal region of hirudin. Chemically, Bivalirudin is sensitive to both oxidation and hydrolysis, requiring careful handling and storage conditions. The drug demonstrates linear pharmacokinetics across therapeutic doses, with plasma clearance primarily occurring through proteolytic cleavage and renal excretion. These properties contribute to its predictable anticoagulation effect and relatively rapid offset of action when discontinued.
Main Applications
The primary clinical application of Bivalirudin is as an anticoagulant during percutaneous coronary intervention (PCI), where it has demonstrated comparable efficacy to heparin with reduced bleeding risks in numerous clinical trials. It is particularly valuable for patients with acute coronary syndromes undergoing early invasive strategies. Another significant application is for patients with heparin-induced thrombocytopenia (HIT) or those at risk of developing HIT, where heparin products are contraindicated. Bivalirudin is also used in some cardiac surgical procedures, especially in patients with HIT requiring cardiopulmonary bypass. Off-label uses include treatment of deep vein thrombosis and pulmonary embolism in heparin-allergic patients, though these applications require careful clinical consideration.
Safety and Storage
Bivalirudin carries a black box warning for increased risks of thrombotic events when used in patients with acute stent thrombosis following PCI. The most common adverse effects include bleeding complications, which can range from minor ecchymosis to life-threatening hemorrhages. Hypersensitivity reactions, though rare, have been reported and require immediate discontinuation. Proper storage is critical for maintaining Bivalirudin's stability. The lyophilized powder should be kept at 2-8°C in its original packaging, protected from light. Reconstituted solutions are stable for 24 hours at room temperature or 48 hours if refrigerated. Strict aseptic techniques must be employed during preparation to prevent microbial contamination of the peptide solution.
B2B Procurement Guide
When procuring Bivalirudin in bulk for pharmaceutical manufacturing or hospital use, buyers should verify the supplier's compliance with current Good Manufacturing Practices (cGMP). Certificates of Analysis should be requested for each batch, confirming identity, purity, and potency specifications. Due to the peptide's sensitivity, cold chain logistics must be maintained throughout transportation. Quality control parameters should include HPLC purity >98%, specified impurity limits, endotoxin testing, and sterility assurance. Large-volume buyers may negotiate pricing based on order quantity, with typical commercial quantities ranging from 10g to 1kg. Consider establishing long-term supply agreements with reputable manufacturers to ensure consistent quality and availability of this critical anticoagulant.
Related Manufacturers
- 主营：联吡啶、甘氨酰、丁烯酸、比伐芦定128270、阻燃剂、酸性橙、西瓜酮、硫酸锰、氯丁烷、甲醇钙、聚合物、肌氨酸、咯喹酮、烷硫酮、磷酸铵、锑酸钠、双噻吩、磷酸铁、中性红、碳酸镍、磷酸铜、异丁酯、氨丁基、浅铬黄、八(6-溴